25 XP   0   0   10

Immunovia publ AB
Buy, Hold or Sell?

Let's analyse Immunovia together

PenkeI guess you are interested in Immunovia publ AB. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Immunovia publ AB. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Immunovia publ AB

I send you an email if I find something interesting about Immunovia publ AB.

Quick analysis of Immunovia (30 sec.)










What can you expect buying and holding a share of Immunovia? (30 sec.)

How much money do you get?

How much money do you get?
kr0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
kr2.06
Expected worth in 1 year
kr-1.27
How sure are you?
12.9%

+ What do you gain per year?

Total Gains per Share
kr-3.33
Return On Investment
-173.7%

For what price can you sell your share?

Current Price per Share
kr1.91
Expected price per share
kr1.248 - kr4.17
How sure are you?
50%

1. Valuation of Immunovia (5 min.)




Live pricePrice per Share (EOD)

kr1.91

2. Growth of Immunovia (5 min.)




Is Immunovia growing?

Current yearPrevious yearGrowGrow %
How rich?$8.5m$29m-$17.3m-147.3%

How much money is Immunovia making?

Current yearPrevious yearGrowGrow %
Making money-$7.1m-$3.3m-$3.8m-53.5%
Net Profit Margin-22,813.8%-14,094.4%--

How much money comes from the company's main activities?

3. Financial Health of Immunovia (5 min.)




4. Comparing to competitors in the Diagnostics & Research industry (5 min.)




  Industry Rankings (Diagnostics & Research)  


Richest
#109 / 145

Most Revenue
#140 / 145

Most Profit
#99 / 145

Most Efficient
#145 / 145

What can you expect buying and holding a share of Immunovia? (5 min.)

Welcome investor! Immunovia's management wants to use your money to grow the business. In return you get a share of Immunovia.

What can you expect buying and holding a share of Immunovia?

First you should know what it really means to hold a share of Immunovia. And how you can make/lose money.

Speculation

The Price per Share of Immunovia is kr1.914. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Immunovia.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Immunovia, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is kr2.06. Based on the TTM, the Book Value Change Per Share is kr-0.83 per quarter. Based on the YOY, the Book Value Change Per Share is kr-1.05 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is kr0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Immunovia.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 kr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Share
Usd Eps-0.10-5.2%-0.16-8.2%-0.09-4.5%-0.09-4.7%-0.07-3.6%
Usd Book Value Change Per Share0.000.0%-0.08-4.0%-0.10-5.0%-0.04-2.0%0.010.3%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.000.0%-0.08-4.0%-0.10-5.0%-0.04-2.0%0.010.3%
Usd Price Per Share0.16-0.25-2.99-8.75-9.31-
Price to Earnings Ratio-0.41--0.55--10.36--33.12--68.48-
Price-to-Total Gains Ratio-2.71--31.41--132.58--191.47-
Price to Book Ratio0.86-0.84-4.69-9.70-14.17-
Price-to-Total Gains Ratio-2.71--31.41--132.58--191.47-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.1758966
Number of shares5685
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.08-0.04
Usd Total Gains Per Share-0.08-0.04
Gains per Quarter (5685 shares)-434.29-212.69
Gains per Year (5685 shares)-1,737.16-850.76
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-1737-17470-851-861
20-3474-34840-1702-1712
30-5211-52210-2552-2563
40-6949-69580-3403-3414
50-8686-86950-4254-4265
60-10423-104320-5105-5116
70-12160-121690-5955-5967
80-13897-139060-6806-6818
90-15634-156430-7657-7669
100-17372-173800-8508-8520

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.031.00.00.0%0.031.00.00.0%
Book Value Change Per Share0.03.01.00.0%0.011.01.00.0%1.018.01.05.0%4.025.02.012.9%4.025.02.012.9%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.031.00.0%0.00.031.00.0%
Total Gains per Share0.03.01.00.0%0.011.01.00.0%1.018.01.05.0%4.025.02.012.9%4.025.02.012.9%

Fundamentals of Immunovia

About Immunovia publ AB

Immunovia AB (publ), a diagnostic company, develops and commercializes blood-based diagnostics for cancer in Sweden and internationally. It offers IMMray PanCan-d, a blood-based test for the early detection of pancreatic cancer. The company was incorporated in 2007 and is headquartered in Lund, Sweden.

Fundamental data was last updated by Penke on 2024-04-22 10:21:02.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Immunovia publ AB.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Immunovia earns for each kr1 of revenue.

  • Above 10% is considered healthy but always compare Immunovia to the Diagnostics & Research industry mean.
  • A Net Profit Margin of -31,612.9% means that kr-316.13 for each kr1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Immunovia publ AB:

  • The MRQ is -31,612.9%. The company is making a huge loss. -2
  • The TTM is -22,813.8%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-31,612.9%TTM-22,813.8%-8,799.1%
TTM-22,813.8%YOY-14,094.4%-8,719.4%
TTM-22,813.8%5Y-41,698.4%+18,884.6%
5Y-41,698.4%10Y-38,412.0%-3,286.4%
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ-31,612.9%-7.7%-31,605.2%
TTM-22,813.8%-6.7%-22,807.1%
YOY-14,094.4%2.4%-14,096.8%
5Y-41,698.4%-1.5%-41,696.9%
10Y-38,412.0%-3.4%-38,408.6%
1.1.2. Return on Assets

Shows how efficient Immunovia is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Immunovia to the Diagnostics & Research industry mean.
  • -32.8% Return on Assets means that Immunovia generated kr-0.33 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Immunovia publ AB:

  • The MRQ is -32.8%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -42.4%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-32.8%TTM-42.4%+9.6%
TTM-42.4%YOY-10.5%-31.8%
TTM-42.4%5Y-14.5%-27.9%
5Y-14.5%10Y-10.9%-3.6%
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ-32.8%-1.7%-31.1%
TTM-42.4%-1.3%-41.1%
YOY-10.5%-0.9%-9.6%
5Y-14.5%-0.5%-14.0%
10Y-10.9%-0.9%-10.0%
1.1.3. Return on Equity

Shows how efficient Immunovia is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Immunovia to the Diagnostics & Research industry mean.
  • -52.6% Return on Equity means Immunovia generated kr-0.53 for each kr1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Immunovia publ AB:

  • The MRQ is -52.6%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -62.9%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-52.6%TTM-62.9%+10.3%
TTM-62.9%YOY-12.8%-50.1%
TTM-62.9%5Y-19.5%-43.3%
5Y-19.5%10Y-14.3%-5.3%
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ-52.6%-0.7%-51.9%
TTM-62.9%-0.1%-62.8%
YOY-12.8%0.3%-13.1%
5Y-19.5%-1.4%-18.1%
10Y-14.3%-2.3%-12.0%

1.2. Operating Efficiency of Immunovia publ AB.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Immunovia is operating .

  • Measures how much profit Immunovia makes for each kr1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Immunovia to the Diagnostics & Research industry mean.
  • An Operating Margin of 0.0% means the company generated kr0.00  for each kr1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Immunovia publ AB:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-14,591.1%+14,591.1%
TTM-14,591.1%YOY-24,304.3%+9,713.2%
TTM-14,591.1%5Y-41,222.1%+26,631.0%
5Y-41,222.1%10Y-38,102.4%-3,119.7%
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ--6.2%+6.2%
TTM-14,591.1%0.5%-14,591.6%
YOY-24,304.3%4.3%-24,308.6%
5Y-41,222.1%3.7%-41,225.8%
10Y-38,102.4%-1.3%-38,101.1%
1.2.2. Operating Ratio

Measures how efficient Immunovia is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Diagnostics & Research industry mean).
  • An Operation Ratio of -317.13 means that the operating costs are kr-317.13 for each kr1 in net sales.

Let's take a look of the Operating Ratio trends of Immunovia publ AB:

  • The MRQ is -317.129.
  • The TTM is 77.295. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ-317.129TTM77.295-394.424
TTM77.295YOY244.073-166.779
TTM77.2955Y414.475-337.181
5Y414.47510Y384.397+30.078
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ-317.1291.296-318.425
TTM77.2951.301+75.994
YOY244.0731.238+242.835
5Y414.4751.268+413.207
10Y384.3971.217+383.180

1.3. Liquidity of Immunovia publ AB.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Immunovia is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Diagnostics & Research industry mean).
  • A Current Ratio of 0.00 means the company has kr0.00 in assets for each kr1 in short-term debts.

Let's take a look of the Current Ratio trends of Immunovia publ AB:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM2.515-2.515
TTM2.515YOY6.753-4.238
TTM2.5155Y8.935-6.420
5Y8.93510Y13.399-4.465
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.111-2.111
TTM2.5152.298+0.217
YOY6.7532.581+4.172
5Y8.9353.012+5.923
10Y13.3993.081+10.318
1.3.2. Quick Ratio

Measures if Immunovia is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Immunovia to the Diagnostics & Research industry mean.
  • A Quick Ratio of 0.00 means the company can pay off kr0.00 for each kr1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Immunovia publ AB:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM2.494-2.494
TTM2.494YOY6.439-3.945
TTM2.4945Y8.804-6.309
5Y8.80410Y13.155-4.351
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ-1.204-1.204
TTM2.4941.285+1.209
YOY6.4391.565+4.874
5Y8.8041.925+6.879
10Y13.1552.128+11.027

1.4. Solvency of Immunovia publ AB.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Immunovia assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Immunovia to Diagnostics & Research industry mean.
  • A Debt to Asset Ratio of 0.38 means that Immunovia assets are financed with 37.7% credit (debt) and the remaining percentage (100% - 37.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Immunovia publ AB:

  • The MRQ is 0.377. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.324. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.377TTM0.324+0.053
TTM0.324YOY0.167+0.157
TTM0.3245Y0.170+0.154
5Y0.17010Y0.125+0.045
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3770.421-0.044
TTM0.3240.407-0.083
YOY0.1670.394-0.227
5Y0.1700.448-0.278
10Y0.1250.446-0.321
1.4.2. Debt to Equity Ratio

Measures if Immunovia is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Immunovia to the Diagnostics & Research industry mean.
  • A Debt to Equity ratio of 60.5% means that company has kr0.60 debt for each kr1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Immunovia publ AB:

  • The MRQ is 0.605. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.490. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.605TTM0.490+0.115
TTM0.490YOY0.201+0.289
TTM0.4905Y0.220+0.270
5Y0.22010Y0.158+0.062
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6050.606-0.001
TTM0.4900.567-0.077
YOY0.2010.631-0.430
5Y0.2200.658-0.438
10Y0.1580.742-0.584

2. Market Valuation of Immunovia publ AB

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every kr1 in earnings Immunovia generates.

  • Above 15 is considered overpriced but always compare Immunovia to the Diagnostics & Research industry mean.
  • A PE ratio of -0.41 means the investor is paying kr-0.41 for every kr1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Immunovia publ AB:

  • The EOD is -0.442. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.409. Based on the earnings, the company is expensive. -2
  • The TTM is -0.547. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.442MRQ-0.409-0.033
MRQ-0.409TTM-0.547+0.138
TTM-0.547YOY-10.363+9.815
TTM-0.5475Y-33.119+32.572
5Y-33.11910Y-68.476+35.356
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
EOD-0.442-0.261-0.181
MRQ-0.409-0.4090.000
TTM-0.547-0.341-0.206
YOY-10.3630.002-10.365
5Y-33.1194.832-37.951
10Y-68.4765.198-73.674
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Immunovia publ AB:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.637+0.637
TTM-0.637YOY-8.473+7.836
TTM-0.6375Y-28.639+28.002
5Y-28.63910Y-41.980+13.341
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ--0.441+0.441
TTM-0.637-1.388+0.751
YOY-8.473-2.079-6.394
5Y-28.639-1.446-27.193
10Y-41.980-1.971-40.009
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Immunovia is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Diagnostics & Research industry mean).
  • A PB ratio of 0.86 means the investor is paying kr0.86 for each kr1 in book value.

Let's take a look of the Price to Book Ratio trends of Immunovia publ AB:

  • The EOD is 0.930. Based on the equity, the company is cheap. +2
  • The MRQ is 0.861. Based on the equity, the company is cheap. +2
  • The TTM is 0.835. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.930MRQ0.861+0.069
MRQ0.861TTM0.835+0.026
TTM0.835YOY4.689-3.854
TTM0.8355Y9.699-8.864
5Y9.69910Y14.169-4.470
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
EOD0.9301.857-0.927
MRQ0.8612.228-1.367
TTM0.8352.222-1.387
YOY4.6893.104+1.585
5Y9.6993.447+6.252
10Y14.1694.036+10.133
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Immunovia publ AB compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share----0.8310%-1.0490%-0.4070%0.066-100%
Book Value Per Share--2.0582.826-27%6.989-71%8.396-75%7.641-73%
Current Ratio---2.515-100%6.753-100%8.935-100%13.399-100%
Debt To Asset Ratio--0.3770.324+16%0.167+126%0.170+122%0.125+202%
Debt To Equity Ratio--0.6050.490+23%0.201+201%0.220+175%0.158+283%
Dividend Per Share----0%-0%-0%-0%
Eps---1.082-1.708+58%-0.928-14%-0.987-9%-0.739-32%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Market Cap86680275.000+7%80249450.000122174353.125-34%1475466750.000-95%4313093189.375-98%4585594577.823-98%
Net Profit Margin---316.129-228.138-28%-140.944-55%-416.984+32%-384.120+22%
Operating Margin----145.9110%-243.0430%-412.2210%-381.0240%
Operating Ratio---317.12977.295-510%244.073-230%414.475-177%384.397-183%
Pb Ratio0.930+7%0.8610.835+3%4.689-82%9.699-91%14.169-94%
Pe Ratio-0.442-8%-0.409-0.547+34%-10.363+2431%-33.119+7989%-68.476+16624%
Price Per Share1.914+7%1.7722.698-34%32.580-95%95.238-98%101.255-98%
Price To Free Cash Flow Ratio----0.6370%-8.4730%-28.6390%-41.9800%
Quick Ratio---2.494-100%6.439-100%8.804-100%13.155-100%
Return On Assets---0.328-0.424+29%-0.105-68%-0.145-56%-0.109-67%
Return On Equity---0.526-0.629+20%-0.128-76%-0.195-63%-0.143-73%
Total Gains Per Share----0.8310%-1.0490%-0.4070%0.066-100%
Usd Book Value--8567009.90011762878.350-27%29088785.350-71%34942815.350-75%31801862.388-73%
Usd Book Value Change Per Share----0.0760%-0.0960%-0.0370%0.006-100%
Usd Book Value Per Share--0.1890.260-27%0.642-71%0.772-75%0.702-73%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.099-0.157+58%-0.085-14%-0.091-9%-0.068-32%
Usd Free Cash Flow----2748476.2750%-4071307.8500%-3540093.6850%-2976464.7060%
Usd Market Cap7965917.273+7%7374924.45511227823.052-34%135595394.325-95%396373264.104-98%421416141.702-98%
Usd Price Per Share0.176+7%0.1630.248-34%2.994-95%8.752-98%9.305-98%
Usd Profit---4503100.000-7168085.125+59%-3332156.150-26%-4013953.060-11%-3016798.522-33%
Usd Revenue--14244.50036185.625-61%26306.375-46%19675.790-28%14650.170-3%
Usd Total Gains Per Share----0.0760%-0.0960%-0.0370%0.006-100%
 EOD+4 -2MRQTTM+7 -14YOY+3 -185Y+4 -1710Y+4 -21

3.2. Fundamental Score

Let's check the fundamental score of Immunovia publ AB based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.442
Price to Book Ratio (EOD)Between0-10.930
Net Profit Margin (MRQ)Greater than0-316.129
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.000
Current Ratio (MRQ)Greater than10.000
Debt to Asset Ratio (MRQ)Less than10.377
Debt to Equity Ratio (MRQ)Less than10.605
Return on Equity (MRQ)Greater than0.15-0.526
Return on Assets (MRQ)Greater than0.05-0.328
Total3/10 (30.0%)

3.3. Technical Score

Let's check the technical score of Immunovia publ AB based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5056.009
Ma 20Greater thanMa 501.668
Ma 50Greater thanMa 1001.564
Ma 100Greater thanMa 2001.688
OpenGreater thanClose2.150
Total4/5 (80.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Other Operating Expenses  51,641-2,03949,602135,892185,494-146,11739,377-88,532-49,155
Total Operating Expenses  50,716-2,15348,563131,431179,994-140,76139,233-88,388-49,155



Latest Balance Sheet

Balance Sheet of 2023-12-31. All numbers in thousands.

Summary
 As reported
Total Liabilities 0
Total Stockholder Equity+ 0
Total Assets = 0

Assets

Total Current Assets
Total Current Assets  (as reported)0
Total Current Assets  (calculated)0
+/-0
Long-term Assets
Long-term Assets  (as reported)0
Long-term Assets  (calculated)0
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities
Total Current Liabilities  (as reported)0
Total Current Liabilities  (calculated)0
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Total Stockholder Equity (as reported)0
Total Stockholder Equity (calculated)0
+/-0
Other
Common Stock Shares Outstanding 34,115



Balance Sheet

All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-06-302014-12-31
> Total Assets 
38,874
37,993
91,509
0
84,320
0
283,409
276,439
268,547
260,202
250,770
233,764
526,205
501,428
477,383
490,758
461,577
445,342
419,366
392,287
734,551
697,089
661,178
635,686
599,984
551,799
493,809
449,546
403,894
360,799
300,589
253,003
190,103
149,594
0
0149,594190,103253,003300,589360,799403,894449,546493,809551,799599,984635,686661,178697,089734,551392,287419,366445,342461,577490,758477,383501,428526,205233,764250,770260,202268,547276,439283,409084,320091,50937,99338,874
   > Total Current Assets 
32,665
24,933
76,953
0
60,757
0
260,925
247,986
231,685
219,227
204,008
177,619
456,932
425,521
398,569
367,436
332,710
303,769
269,158
231,848
563,535
517,836
474,796
433,172
393,745
348,580
297,102
249,364
207,159
168,367
115,615
77,719
150,583
112,592
0
0112,592150,58377,719115,615168,367207,159249,364297,102348,580393,745433,172474,796517,836563,535231,848269,158303,769332,710367,436398,569425,521456,932177,619204,008219,227231,685247,986260,925060,757076,95324,93332,665
       Cash And Cash Equivalents 
31,804
22,761
75,767
0
59,728
0
259,094
246,361
228,326
215,300
192,426
167,790
447,212
415,602
386,136
359,849
327,462
297,217
263,345
222,915
556,191
510,593
468,462
425,397
381,550
339,165
287,406
239,796
197,447
158,839
106,041
68,237
143,878
106,677
0
0106,677143,87868,237106,041158,839197,447239,796287,406339,165381,550425,397468,462510,593556,191222,915263,345297,217327,462359,849386,136415,602447,212167,790192,426215,300228,326246,361259,094059,728075,76722,76131,804
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
219
3,409
8,934
7,344
7,243
4,353
7,775
10,209
8,103
72
64
20
128
3,648
7,141
6,705
5,915
0
05,9156,7057,1413,6481282064728,10310,2097,7754,3537,2437,3448,9343,40921900000000000000000
       Other Current Assets 
861
2,173
1,186
0
1,029
0
1,830
1,625
3,359
3,927
11,583
9,829
9,720
9,919
12,434
7,587
1
6,552
5,813
-1
7,344
7,243
6,334
7,775
10,209
8,103
7,546
8,029
8,116
8,127
3,910
6,979
6,582
5,915
0
05,9156,5826,9793,9108,1278,1168,0297,5468,10310,2097,7756,3347,2437,344-15,8136,55217,58712,4349,9199,7209,82911,5833,9273,3591,6251,83001,02901,1862,173861
   > Long-term Assets 
6,209
13,060
14,556
0
23,563
0
22,485
28,453
36,862
40,975
46,761
56,145
69,273
75,907
78,814
123,322
128,868
141,573
150,208
160,439
171,016
179,253
186,382
202,514
206,239
203,219
196,707
200,182
196,735
192,432
184,974
175,284
39,520
37,002
0
037,00239,520175,284184,974192,432196,735200,182196,707203,219206,239202,514186,382179,253171,016160,439150,208141,573128,868123,32278,81475,90769,27356,14546,76140,97536,86228,45322,485023,563014,55613,0606,209
       Property Plant Equipment 
740
778
671
0
948
0
3,002
2,842
5,142
4,922
7,211
9,654
14,956
14,310
14,044
51,383
50,367
55,358
55,224
53,442
51,595
51,225
48,700
53,642
50,542
49,044
46,527
53,264
52,846
51,577
47,877
45,210
36,602
34,207
0
034,20736,60245,21047,87751,57752,84653,26446,52749,04450,54253,64248,70051,22551,59553,44255,22455,35850,36751,38314,04414,31014,9569,6547,2114,9225,1422,8423,00209480671778740
       Intangible Assets 
5,469
12,282
13,885
0
22,615
0
19,482
0
0
0
36,791
0
51,312
58,627
61,786
0
0
0
91,859
103,618
116,286
125,014
134,935
145,946
152,843
151,227
146,548
143,811
140,462
137,126
133,597
130,071
2,914
2,792
0
02,7922,914130,071133,597137,126140,462143,811146,548151,227152,843145,946134,935125,014116,286103,61891,85900061,78658,62751,312036,79100019,482022,615013,88512,2825,469
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,112
-1
3,292
74,338
3,379
3,135
3,014
113,980
2,926
2,854
2,948
125,525
3,107
0
3,729
0
0
4
0
0
004003,72903,107125,5252,9482,8542,926113,9803,0143,1353,37974,3383,292-13,112000000000000000
> Total Liabilities 
3,131
6,009
7,708
0
5,623
0
6,778
7,579
9,768
8,089
13,974
14,399
22,868
13,679
15,431
55,929
56,545
57,330
61,761
66,336
65,796
64,018
61,775
64,293
75,915
67,385
59,905
62,489
64,903
64,544
56,786
58,730
58,832
56,373
0
056,37358,83258,73056,78664,54464,90362,48959,90567,38575,91564,29361,77564,01865,79666,33661,76157,33056,54555,92915,43113,67922,86814,39913,9748,0899,7687,5796,77805,62307,7086,0093,131
   > Total Current Liabilities 
3,131
6,009
7,708
0
5,624
0
6,778
7,579
9,768
8,089
13,974
14,399
22,868
13,679
15,431
25,775
27,299
22,641
28,641
34,483
35,266
33,118
33,787
32,608
45,720
38,711
32,750
26,424
29,287
29,532
24,086
29,141
35,929
35,186
0
035,18635,92929,14124,08629,53229,28726,42432,75038,71145,72032,60833,78733,11835,26634,48328,64122,64127,29925,77515,43113,67922,86814,39913,9748,0899,7687,5796,77805,62407,7086,0093,131
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,057
4,087
3,323
4,596
4,993
5,043
3,475
5,143
5,864
5,838
5,861
6,106
4,682
4,770
4,857
4,874
6,347
5,051
5,101
0
05,1015,0516,3474,8744,8574,7704,6826,1065,8615,8385,8645,1433,4755,0434,9934,5963,3234,0874,057000000000000000
       Accounts payable 
1,164
4,117
1,252
0
1,533
0
2,422
0
0
0
7,470
0
0
0
3,031
0
0
0
5,426
0
0
0
4,255
0
0
0
3,067
0
24,517
24,675
1,577
22,794
30,878
30,085
0
030,08530,87822,7941,57724,67524,51703,0670004,2550005,4260003,0310007,4700002,42201,53301,2524,1171,164
       Other Current Liabilities 
1,967
1,892
6,456
0
4,091
0
4,356
7,579
9,768
8,089
6,504
14,399
22,868
13,679
12,400
21,718
23,212
19,318
2,269
29,490
30,223
29,643
2,441
26,744
39,882
32,850
3,366
21,742
24,517
24,675
17,635
22,794
30,878
30,085
0
030,08530,87822,79417,63524,67524,51721,7423,36632,85039,88226,7442,44129,64330,22329,4902,26919,31823,21221,71812,40013,67922,86814,3996,5048,0899,7687,5794,35604,09106,4561,8921,967
   > Long-term Liabilities 
0
0
0
0
-1
0
0
0
0
0
0
0
0
0
0
30,154
29,246
34,689
33,120
31,853
30,530
30,900
27,988
31,685
30,195
28,674
27,155
36,065
35,616
35,012
32,700
29,589
22,903
21,187
0
021,18722,90329,58932,70035,01235,61636,06527,15528,67430,19531,68527,98830,90030,53031,85333,12034,68929,24630,1540000000000-10000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
30,900
27,988
31,685
30,195
28,674
27,156
36,065
35,616
35,012
32,700
29,589
22,903
21,187
0
021,18722,90329,58932,70035,01235,61636,06527,15628,67430,19531,68527,98830,900000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
71,213
0
0
0
111,234
0
0
0
122,492
0
0
0
0
0
0
0
0
00000000122,492000111,23400071,213000000000000000000
> Total Stockholder Equity
35,743
31,984
83,801
0
78,697
0
276,631
268,860
258,779
252,113
236,795
219,365
503,337
487,749
461,952
434,829
405,032
388,012
357,605
325,951
668,755
633,071
599,403
571,393
524,069
484,414
433,904
387,057
338,991
296,255
243,803
194,273
131,271
93,221
0
093,221131,271194,273243,803296,255338,991387,057433,904484,414524,069571,393599,403633,071668,755325,951357,605388,012405,032434,829461,952487,749503,337219,365236,795252,113258,779268,860276,631078,697083,80131,98435,743
   Common Stock
221
221
715
0
715
0
840
840
840
840
866
866
974
977
977
977
977
983
983
983
1,130
1,130
1,132
1,132
1,132
1,132
1,132
1,132
1,132
1,132
1,132
1,132
2,264
2,264
0
02,2642,2641,1321,1321,1321,1321,1321,1321,1321,1321,1321,1321,1301,13098398398397797797797797486686684084084084007150715221221
   Retained Earnings 
-4,045
31,715
28,138
0
70,521
0
-33,009
-40,780
-51,334
-62,923
-78,241
-95,567
-121,721
-139,125
-164,779
-191,163
-221,059
-246,685
-279,300
-307,051
-341,150
-379,214
-425,334
-448,779
-498,041
-534,171
-581,300
-625,412
-659,138
-682,070
-749,392
-801,050
-971,255
-1,009,811
0
0-1,009,811-971,255-801,050-749,392-682,070-659,138-625,412-581,300-534,171-498,041-448,779-425,334-379,214-341,150-307,051-279,300-246,685-221,059-191,163-164,779-139,125-121,721-95,567-78,241-62,923-51,334-40,780-33,009070,521028,13831,715-4,045
   Capital Surplus 00000000000000000000000000000000000
   Treasury Stock00000000000000000000000000000000000
   Other Stockholders Equity 
39,567
48
54,948
0
7,461
0
308,799
308,800
309,273
314,196
314,170
314,066
624,084
625,897
625,755
625,015
625,114
633,714
635,922
632,019
1,008,775
1,011,155
1,023,605
1,019,040
1,020,978
1,017,453
1,014,072
1,011,337
996,997
977,193
992,063
994,191
1,100,262
1,100,768
0
01,100,7681,100,262994,191992,063977,193996,9971,011,3371,014,0721,017,4531,020,9781,019,0401,023,6051,011,1551,008,775632,019635,922633,714625,114625,015625,755625,897624,084314,066314,170314,196309,273308,800308,79907,461054,9484839,567



Balance Sheet

All numbers in thousands.




Cash Flow

Currency in SEK. All numbers in thousands.




Income Statement

Currency in SEK. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue1,574
Cost of Revenue-7,607
Gross Profit1,574-6,033
 
Operating Income (+$)
Gross Profit1,574
Operating Expense--310,993
Operating Income-309,419312,567
 
Operating Expense (+$)
Research Development0
Selling General Administrative0
Selling And Marketing Expenses0
Operating Expense-310,9930
 
Net Interest Income (+$)
Interest Income22,841
Interest Expense-4,678
Other Finance Cost-45,682
Net Interest Income-27,519
 
Pretax Income (+$)
Operating Income-309,419
Net Interest Income-27,519
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-327,741-305,812
EBIT - interestExpense = -327,741
0
-304,741
Interest Expense4,678
Earnings Before Interest and Taxes (EBIT)-323,063-323,063
Earnings Before Interest and Taxes (EBITDA)-309,419
 
After tax Income (+$)
Income Before Tax-327,741
Tax Provision-0
Net Income From Continuing Ops-327,741-327,741
Net Income-309,419
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses-310,993
Total Other Income/Expenses Net-3,60727,519
 

Technical Analysis of Immunovia
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Immunovia. The general trend of Immunovia is BULLISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Immunovia's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (57.1%) Bearish trend (-57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Immunovia publ AB.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 2.85 < 3 < 4.17.

The bearish price targets are: 1.77 > 1.538 > 1.248.

Tweet this
Immunovia publ AB Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Immunovia publ AB. The current mas is .

The long score for the Moving Averages is 11/14.
The longshort score for the Moving Averages is 8/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Immunovia publ AB Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Immunovia publ AB. The current macd is 0.11267216.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Immunovia price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Immunovia. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Immunovia price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Immunovia publ AB Daily Moving Average Convergence/Divergence (MACD) ChartImmunovia publ AB Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Immunovia publ AB. The current adx is 30.02.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Immunovia shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
Immunovia publ AB Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Immunovia publ AB. The current sar is 1.7.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Immunovia publ AB Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Immunovia publ AB. The current rsi is 56.01. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending down: The RSI is trending down. -1
Immunovia publ AB Daily Relative Strength Index (RSI) ChartImmunovia publ AB Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Immunovia publ AB. The current phase is Correction in bull market.

The long score for the Stochastic Oscillator is 2/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Immunovia price going up in the near term. +2
  • Trending down: The STOCH %K is trending down. -1
Immunovia publ AB Daily Stochastic Oscillator ChartImmunovia publ AB Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Immunovia publ AB. The current cci is 68.49.

Immunovia publ AB Daily Commodity Channel Index (CCI) ChartImmunovia publ AB Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Immunovia publ AB. The current cmo is 12.69.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Immunovia publ AB Daily Chande Momentum Oscillator (CMO) ChartImmunovia publ AB Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Immunovia publ AB. The current willr is -61.01694915.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Immunovia is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Immunovia publ AB Daily Williams %R ChartImmunovia publ AB Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Immunovia publ AB.

Immunovia publ AB Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Immunovia publ AB. The current atr is 0.27925339.

Immunovia publ AB Daily Average True Range (ATR) ChartImmunovia publ AB Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Immunovia publ AB. The current obv is 16,737,945.

Immunovia publ AB Daily On-Balance Volume (OBV) ChartImmunovia publ AB Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Immunovia publ AB. The current mfi is 62.66.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Immunovia publ AB Daily Money Flow Index (MFI) ChartImmunovia publ AB Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Immunovia publ AB.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-01STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-11WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-22CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-29CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-09CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-10STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-11STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-16WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-19STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-22CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-29STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-31STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-07WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-08STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-09STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-15SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-16MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-21SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-22CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-26MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-29DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-08MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-13STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-18STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-21CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-22SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-04-03DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-09SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-04-10RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-04-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-22STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).

6.3. Candlestick Patterns

Immunovia publ AB Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Immunovia publ AB based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5056.009
Ma 20Greater thanMa 501.668
Ma 50Greater thanMa 1001.564
Ma 100Greater thanMa 2001.688
OpenGreater thanClose2.150
Total4/5 (80.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Immunovia with someone you think should read this too:
  • Are you bullish or bearish on Immunovia? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Immunovia? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Immunovia publ AB

I send you an email if I find something interesting about Immunovia publ AB.


Comments

How you think about this?

Leave a comment

Stay informed about Immunovia publ AB.

Receive notifications about Immunovia publ AB in your mailbox!